4.1 Article

Profitable gifts -: A history of the Merck Mectizan® donation program and its implications for international health

Journal

PERSPECTIVES IN BIOLOGY AND MEDICINE
Volume 47, Issue 1, Pages 100-109

Publisher

JOHNS HOPKINS UNIV PRESS
DOI: 10.1353/pbm.2004.0004

Keywords

-

Ask authors/readers for more resources

A unique public/private partnership situated around a pharmaceutical, Merck's Mectizan((R)) donation program stands out as an example of corporate philanthropy in the history of the pharmaceutical industry and provides insight into future public/private partnerships in public health. This paper considers the issues Merck faced in the decision to donate Mectizan (ivermectin) and in the subsequent development of the Mectizan donation program, delineating the moral and financial debates that arose within the company. Corning after almost 15 years of donation, this assessment of the program's strengths and shortcomings suggests how the pharmaceutical industry can better serve as a viable partner in improving international health.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available